BioSpace News Archive

Lumos Pharma, Inc. announced that interim data from its OraGrowtH210 and OraGrowtH212 Trials will be reviewed in two oral presentations in Session OR21 – “Update on Growth Disorders” at the 2023 Annual Meeting of the Endocrine Society, held in Chicago, Illinois, June 15-18, 2023.

Ocean Biomedical announced that it is expected to be added to the Russell 2000® Index, effective after the U.S. market opens on June 26, 2023.

Transgene and BioInvent International AB announce positive Phase Ia data on the oncolytic virus BT-001 for the treatment of solid tumors.

ISA Pharmaceuticals B.V. announces that it will present the first clinical data of the combination of ISA101b and Regeneron’s PD-1 inhibitor Libtayo® in patients with recurrent metastatic Human Papilloma Virus type 16 induced head and neck cancers who progressed on pembrolizumab or nivolumab.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 trial of oral rigosertib plus the PD-1 inhibitor pembrolizumab in patients with metastatic melanoma who have progressed on prior PD-1/L1 inhibitor therapy.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the first patient has been enrolled and safely dosed at a European clinical site for its integrated Phase II/III AIPAC-003 trial in metastatic breast cancer.

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as ‘Lynk Pharmaceuticals’), an innovative clinical stage company, announced that it has dosed the first cohort of psoriatic patients in a Phase Ib clinical trial of its innovative drug LNK01004.

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces the results of resolutions presented at its Combined General Meeting, held on May 24, 2023, and made them available on the dedicated section of its website.